CRVS News and Press, Corvus Pharmaceuticals Inc. From 12/08/23

2023-12-08 15:00:12 ET More on the markets S&P 500: New All-Time Highs Before A Major Sell-Off S&P 500 Forecast 2024: Muddling Through Only Thing That Matters Is Price; Nasdaq Has Further To Go - Cestrian Capital Research Money market funds attract mo...

2023-11-07 22:46:06 ET Corvus Pharmaceuticals, Inc. (CRVS) Q3 2023 Earnings Conference Call November 7, 2023, 04:30 PM ET Company Participants Zack Kubow - Real Chemistry Leiv Lea - CFO Richard Miller - CEO Jim Rosenbaum - SVP of Research Conference Cal...

2023-11-07 16:10:19 ET More on Corvus Pharmaceuticals Corvus gains as Oppenheimer starts with a bullish view on pipeline Seeking Alpha’s Quant Rating on Corvus Pharmaceuticals Historical earnings data for Corvus Pharmaceuticals Financial information fo...

Protocol finalized for soquelitinib (CPI-818) Phase 3 registrational clinical trial in peripheral T cell lymphoma (PTCL); multiple sites preparing to initiate trial enrollment New data from soquelitinib Phase 1 T cell lymphoma trial accepted for presentation at the 65th ASH Annual Meeti...

Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...

Corvus Pharmaceuticals Inc. (CRVS) is expected to report $-0.16 for Q3 2023

BURLINGAME, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new interim data from its Phase 1/1b trial of soquelitinib in patients with relapsed peripheral T cell lymphoma ...

Data demonstrated soquelitinib was active in six inflammatory/immune disease models and provides rationale for development in a range of additional Th2- and Th17-mediated diseases Soquelitinib’s unique mechanism of action inhibited the production of Th2 and Th17 cells, providing ...

BURLINGAME, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 7, 2023 at 4:30 pm ET (1:30 pm PT) to provide a business update ...

2023-09-07 13:24:40 ET Gainers: Solowin Holdings SWIN +174% . Wheeler Real Estate Investment Trust WHLR +50% . Rosecliff Acquisition Corp I ( RCLF ) +47% . Semantix ( STIX ) +41% . Hitek Global ( HKIT ) +21% . Biodexa Pharmaceuticals...